|
|
home > about us Since 1901 Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Paris, France, Guerbet is a publicly traded company holding more than 25% of the European market share and 7% of the worldwide contrast media market. The Guerbet product portfolio is marketed in 130 countries worldwide and contains contrast agents for X-ray and MRI modalities: Oxilan®, Hexabrix®(1), Dotarem®(2), Lumirem®(2), Endorem®(2) and others. Guerbet dedicates the best talent and resources to new drug development, currently having multiple agents in Phase III clinical trials. Guerbet LLC, the U.S. subsidiary, was established in January of 2002 by purchasing the assets of Oxilan® from Cook, one of the leaders in the medical device industry. Currently Guerbet LLC is responsible for the marketing, sales and distribution of Oxilan® (ioxilan) Injection and Hexabrix® sodium and meglumine ioxaglate. In addition, steps are underway to seek approval for new products in the U.S. market. Currently Guerbet LLC is responsible for the marketing, sales and distribution of Oxilan® (ioxilan) Injection, a non-ionic contrast medium for diagnostic and interventional procedures, and Hexabrix® (sodium and meglumine ioxaglate), a low-osmolar ionic contrast medium for interventional cardiac procedures. (1) Comarketed in the U.S. with Covidien Imaging Solutions |
